Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-09-28

Schrodinger, Inc.

Schrödinger sells molecular modeling and discovery workflow software and also monetizes collaborative and proprietary small-molecule drug programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From modeling tool to discovery control layer

The upside case is a business-model upgrade, not a moonshot drug win. If the company turns trusted scientific tools into a broader AI-native workflow layer, revenue quality and wallet share can improve enough to support meaningful equity compounding.

Analysis

Thesis

Over five years, SDGR can move from specialist modeling software to a governed discovery operating layer: hosted delivery, LiveDesign, and Bunsen deepen workflow control, while partner and spinout structures preserve drug upside without forcing balance-sheet-heavy biotech spending.

Last Economy Alignment

AI should expand the number of experiments and users that need Schrödinger’s validated workflows, but it does not own the core compute or exclusive data rails, so value capture depends on staying embedded in pharma workflows.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.6x (from 5 most recent analyses)

Reasoning

This is mainly a software-quality compounding case, not a single-drug jackpot case. If Bunsen broadens usage across existing pharma accounts, hosted delivery improves contract quality, and spinout structures keep discovery upside off the balance sheet, Schrödinger can grow into a much larger revenue base while keeping a respectable software-style multiple. If those proof points stall, the upside compresses fast.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is economic capture, not scientific relevance. Schrödinger likely remains useful, but returns disappoint if Bunsen expands activity without creating a larger, stickier workflow budget, if top-account concentration stays high, or if collaboration volatility and cash burn force the company to self-fund too much biotech optionality.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material operating disclosure appeared in the last 7-10 days; the setup is still waiting on the next ACV and hosted-mix proof point.
The shares remained close to the 52-week high reached on September 22, 2026, so expectations have risen faster than fundamentals changed.
No newer announcement has displaced the September 9 Tectora transaction as the main evidence for a capital-light spinout monetization path.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.40

They control trusted scientific workflows that drug teams already use, and AI can make those workflows useful to many more researchers. The risk is that cheaper open tools or in-house pharma agents keep Schrödinger scientifically relevant but weaken how much money it captures.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.43

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research